Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
The promise of 'personalized cancer care' with therapies toward specific molecular aberrations has potential to improve outcomes. However, there is recognized heterogeneity within any given tumor-type from patient to patient and within an individual as demonstrated by molecular evolution through space and time. These issues have become hurdles to advancing cancer treatment outcomes with novel molecularly targeted agents.
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi